

Supplementary Information

Table of Contents

Supplementary Table 1. Antibody information.

Supplementary Table 2: Abundance values of significantly enriched proteins detected in mass spectrometry.

Supplementary Table 3: Genetic variants identified in *NXT2* and *NXF3*.

Supplementary Table 4. Clinical data of infertile men with *NXT2/NXF3* variants.

Supplementary Table 5. Analysis of M3065's familial exome sequencing data does not identify other variants that co-segregate and are candidates to cause the phenotype.

Supplementary Table 6. Primer information.

Supplementary Figure 1. *NXT2/NXF3* antibody validation.

Supplementary Figure 2. Protein structures of *NXT1*, *NXT2*, *NXF1*, *NXF2* and *NXF3*.

Supplementary Figure 3. Western blot analysis of *NXF2* and *NXF3* proteins expressed from deletion constructs lacking the NTF2-like domain or RRM domain.

Supplementary Figure 4. The *NXT2* protein region downstream of the NTF2-like domain is not essential for binding to *NXF2* and *NXF3*.

Supplementary Figure 5. The *NXT2* missense variant c.268G>T p.(Ala90Ser) in M2004 has an impact on splicing but no identified effect on protein level.

Supplementary Figure 6. scRNA-seq shows expression of nuclear export factor proteins in fetal male germ cells and adult testis.

Supplementary References

Supplementary Table 1. Antibody information.

Antibody	Company, catalogue #, source species, clonality, LOT	Dilution, application, special protocol requirements
Primary Antibodies		
α - α/β -Tubulin	Cell Signaling Technology, #2148, rabbit, polyclonal, 8	1:250 (ICC)
α -FLAG	Merck, #F3165, mouse, monoclonal, SLCJ3741	1:1500 (Western blot)
α -GAPDH	Cell Signaling Technology, #5174, rabbit, monoclonal, 8	1:1500 (Western blot)
α -HA	Roche, #11867423, rat, monoclonal, 65506600	1:2000 (Western blot)
α -IgG	Cell Signaling Technology, #2729, rabbit, polyclonal, I5006	5 μ g (pulldown of testicular lysates)
α -MAGEA4	Abcam, #ab139297, mouse, monoclonal, GR3177245-18	1:500 in 5 % BSA/TBS (IHC)
α -NXF3	Merck, #HPA046757, rabbit, polyclonal, R43903	1:500 (Western blot) 1:250 (ICC)
α -NXT2	Merck, #HPA072010, rabbit, polyclonal, R102934	5 μ g (pulldown of testicular lysates) 1:1000 (Western blot) 1:50 in 5 % BSA/TBS (IHC)
α -SOX9	Sigma Aldrich, #AB5535, rabbit, polyclonal, 3481414	1:1000 in 5 % BSA/TBS (IHC)
Secondary Antibodies		
α -mouse	Abcam, #5886, goat, monoclonal, GR195138-16	1:100 in 5 % BSA/TBS (IHC)
α -mouse IgGk BP-HRP	Santa Cruz Biotechnology, #sc-516102, donkey, monoclonal, F1620	1:1000 (Western blot)
α -rabbit	Abcam, #ab6012, goat, monoclonal, GR3353084-9	1:100 in 5 % BSA/TBS (IHC)
α -rabbit Alexa Fluor Plus 488	Thermo Scientific, #A32790, donkey, monoclonal, VE306220	1:250 (ICC)
α -rabbit IgG HRP	Santa Cruz Biotechnology, #sc-2357, mouse, monoclonal, E0819	1:1000 (Western blot)
α -rat HRP	Merck, #A9037, goat, monoclonal	1:2000 (Western blot)

Supplementary Table 2: Abundance values of significantly enriched proteins detected in mass spectrometry.

	Testis tissue of one transgender person					Pooled testis tissue of biopsies of three persons with obstructive azoospermia	
Protein	Abundance IgG 1	Abundance IgG 2	Abundance NXT2 1	Abundance NXT2 2	Abundance NXT2 3	Abundance NXT2 4	T-Test
NXF1	14230731.38	14016786.41	375889307.8	403762086	388763931.2	411400234.9	1.96331E-05
NXT2	18103574.63	25231497.75	765580724.5	937477492	912382921	904036323.8	0.000182886
NXF3	22481439	23742693.63	1082563670	1182345274	1165130874	954071612.1	0.000249814
NUP214	27171387.25	26968132.5	156840915.1	176367369.6	192071882.8	148902529.1	0.000705988
NXF2	36633030.38	27647722.47	146708530.4	143763023	122286826.6	108888490.3	0.000658747
SPATA5	7206384.125	6383698.625	69633338.38	104406044.5	80504325.5	96207154.25	0.001873179
SPATA5L1	3749882.688	5475614.438	31508764.69	50992627.25	46634457.06	54747581.31	0.003342401
NUP98	11591541.44	15308999.5	24356397.69	28445671.75	32517270.75	38240065.5	0.007674736

Supplementary Table 3: Genetic variants identified in *NXT2* and *NXF3*.

Subject ID	Gene	Variant g.	Variant c.	Variant p.	Genotype	MAF (gnomAD v2.1.1/v4.1.0)	LoF o/e fraction (gnomAD v2.1.1)	LoF o/e upper bound fraction (LOEUF) (gnomAD v2.1.1)
M2004	<i>NXT2</i>	chrX:108,784,704G>T	c.268G>T	p.(Ala90Ser)	hem.	0.00002909 / 0.0001080	0	0.51
M3065	<i>NXT2</i>	chrX:108,784,790dup	c.354dup	p.(Asp119*)	hem.	-		
RU00584	<i>NXT2</i>	chrX:108,765,361-108,807,493del			hem.	-		
M2799	<i>NXF3</i>	chrX:102,337,247G>T	c.826G>T	p.(Gly276*)	hem.	-	0.33	0.6

Supplementary Table 4: Clinical data of infertile men with *NXT2/NXF3* variants.

Individual	Genotype	Andrological phenotype	Testicular phenotype (PAS/MAGEA4), TESE outcome
M2004	<i>NXT2</i> : g.108,784,704 c.268G>T p.(Ala90Ser)	FSH: 9.4 LH: 3.2 T: 15.4 TV: 20/20 Azoospermia	98 % SCO, 2 % TS/ no germ cells detected no sperm retrieved
RU00584	<i>NXT2</i> : g.108,765,361- 108,807,493del ¹	FSH: 14.9 LH: 4.7 T: 9.6 TV: 10/12 Azoospermia	SCO/no germ cells detected no sperm retrieved, some spermatozoa seen during inspection of biopsy-derived cell suspension - due to their very abnormal morphology material was not cryopreserved
M3065	<i>NXT2</i> : g.108,784,790dup c.354dup p.(Asp119*)	FSH: 63.8 LH: 9.7 T: 12.7 TV: 3/3 Azoospermia	70 % SCO, 30 % TS/ focal spermatogenesis in ~7 % (11/161) of seminiferous tubules no sperm retrieved
M2799	<i>NXF3</i> : g.102,337,247 c.826G>T p.(Gly276*)	FSH: 4.7 LH: 5.8 T: 20.5 TV: 17/18 Oligoasthenoteratozoospermia	no biopsy performed

TESE: testicular sperm extraction, FSH: follicle stimulating hormone (IU/L), LH: luteinizing hormone (IU/L), T: testosterone (nmol/L), TV: testicular volume right/left (mL), SCO: Sertoli cell-only, TS: tubular shadows | Reference values: FSH 1-7 IU/L, LH 2-10 IU/L, T >12 nmol/L, TV >12 mL per testis.


Supplementary Table 5. Analysis of M3065's familial exome sequencing data does not identify other variants that co-segregate and are candidates to cause the phenotype.

Gene	Chr.	Variant c.	Variant p.	Consequence	MAF (gnomAD)	CADD
ELF4	X	c.1810C>T	p.(Arg604Cys)	missense variant	0.26 %	20.7
NLGN3	X	c.63C>A	p.(Ser21Arg)	missense variant	0.01 %	17.35
RIPPLY1	X	c.362A>G	p.(Asn121Ser)	missense variant	0.08 %	19.26
TIMP1	X	c.195G>T	p.(Met65Ile)	missense variant	0.03 %	18.83

Supplementary Table 6: Primer information.


Sanger Sequencing	
<i>NXT2</i> c.268G>T	
Forward	5'-CCAGTGGAGATGGAGCAAGG-3'
Reverse	5'-ATCCAGCCCTGAAACAGCAT-3'
<i>NXT2</i> c.354dup	
Forward	5'-CCAGTGGAGATGGAGCAAGG-3'
Reverse	5'-GTTTCTCGCTGCTTTTGGTGT-3'
<i>NXF3</i> c.826G>T	
Forward	5'-TGCAGAAGGGCGCTATCAAA-3'
Reverse	5'-AGAAAAGGGGGAGGAGGGT-3'
Minigene assay	
<i>NXT2</i> c.268G>T (Initial amplification)	
Forward	5'-CACCACACTAAAAGTGGCTTGGGG-3'
Reverse	5'-GACATTTTCAGGGTCCAGCAG-3'
Minigene exon primers (Rat <i>INS2</i> exons 3 and 4)	
Forward	5'-CCTGCTCATCCTCTGGGAGC-3'
Reverse	5'-AGGTCTGAAGGTCACGGGCC-3'
Cloning of cDNA constructs	
<i>NXT2</i> (NM_018698.5)	
Forward	5'-GGTGGTAAGCTTATGAGAAAATACAGAAGCCACTGGTC-3'
Reverse	5'-GGTGGTCTCGAGTTAACTACTAGACCAATCTTGA AACCG-3'
<i>NXF2</i> (NM_022053.4)	
Forward	5'-GGTGGTAAGCTTATGTGCTCTACTCTAAAGAAGTGTGGG-3'
Reverse	5'-GGTGGTCTCGAGTTAGGAGATTTGCTTGAAGGCCTCCGCG-3'
<i>NXF3</i> (NM_022052.2)	
Forward	5'-GGTGGTGAATTCATGTCACTGCCTTCAGGACACACTACG -3'
Reverse	5'-GGTGGTCTCGAGTTACGAAGGCAGCATTCTGCTGCTCC-3'
Primers for cloning of 5' Kozac sequence (phosphorylated)	
<i>NXF2</i>	
Forward	5'-ATGTGCTCTACTCTAAAGAAGTG-3'
Reverse	5'-GGTGGCAAGCTTAAAGTTAAACGCTAGCCA-3'
<i>NXF3</i>	
Forward	5'-ATGGACTACAAAGACGATGACGA-3'
Reverse	5'-GGTGGCGAATTCCACCACACTGGACTAGTG-3'
Primers for cloning of tags and for introducing deletions (phosphorylated)	
<i>NXT2</i> (HA tag)	
Forward	5'-AGAAAATACAGAAGCCACTGGTC-3'
Reverse	5'-AGCGTAATCTGGAACATCGTATGGGTACATAAGCTTAAAGTTTAA-ACGCTAG-3'
<i>NXF2</i> (3xFLAG tag)	
Forward	5'-CACGACATCGACTACAAGGACGACGACGACAAGTGATAAGTCTAGAGGGCCCGTTTAAACC-3'
Forward 2	5'-GACTACAAGGACCACGACGGTACTACAAGGACCACGACATCGACTACAAGGACGACG-3'
Reverse	5'-GGAGATTTGCTTGAAGGCCTCC-3'

NXF3 (FLAG tag)	
Forward	5'-TCACTGCCTTCAGGACACACTAC-3'
Reverse	5'-CTTGTCGTCATCGTCTTTGTAGTCCATGAATTCCACCACACTGG- ACTA-3'
NXT2 (AA137-142del)	
Forward	5'-AAAACGGAAGCAATCACTTGCAA-3'
Reverse	5'-TAACTCGAGTCTAGAGGGCCCGT-3'
NXF2 (NTF2LD_del)	
Forward	5'-AGGGATGCCAGCCCCCAAGAGAC-3'
Reverse	5'-ATGCTTTAGGGTCTCAGATCCAG-3'
NXF3 (NTF2LD_del)	
Forward	5'-CGGGATACCAGCCACCAAGGGAC-3'
Reverse	5'-ATTCTTCAACATCTCAGATCCAA-3'
NXF2 (RRMD_del)	
Forward	5'-TCTGTGAAGAATAAGTTGAAGCC-3'
Reverse	5'-GTTCTTGTGTATCCATCCTGTG-3'
NXF3 (RRMD_del)	
Forward	5'-TTTGTGCACAGGGAGCTGAAGTC-3'
Reverse	5'-GCTCCCTAAGGTCCCATCCGGCA-3'
Primers for site-directed-mutagenesis	
NXT2 (c.268G>T)	
Forward	5'-CGGTCACTAACCAGGCTGTATCTGGAC-3'
Reverse	5'-GGTTAGTGACCGTCTTCTTTTATCCATTGTCTC-3'
NXT2 (c.354dup)	
Forward	5'-CTAAATAATTTTTTTTTGACACATTGCCTTCTAGTGAGTTC-3'
Reverse	5'-GTGTCAAAAAAATTATTTAGGGCATCCAGCCCTG-3'
NXF3 (c.826G>T)	
Forward	5'-AGCCATGAGAGAAGTGTGCGGACAGAAGCC-3'
Reverse	5'-ACTTCTCTCATGGCTCTATCCCTTCCACTTGTC-3'




Supplementary Figure 1. NXT2/NXF3 antibody validation.

a. Western blot analysis of protein lysates isolated from HEK cells transfected with HA-tagged NXT2 indicating specific staining of the recombinant NXT2 protein with both HA-tag antibody and NXT2 antibody (HPA072010). Both approaches resulted in a distinct band with the expected size of ~26 kDa. b. In lysates of native human testicular tissue NXT2 was specifically detected with the NXT2 antibody (HPA072010). c. Western blot analysis of protein lysates isolated from HEK cells transfected with FLAG-tagged NXF3 indicating specific staining of the recombinant NXF3 protein with FLAG-tag antibody and NXF3 antibody (HPA072010). Both Western blots resulted in a distinct band with the expected size of ~60 kD. d. In native testicular tissue lysates, NXF3 can be detected using the NXF3 specific antibody (HPA046757). Uncropped images of all Western blots depicted are provided in the Source data file.




Supplementary Figure 2. Protein structures of NXT1, NXT2, NXF1, NXF2, and NXF3.

NXT1 and NXT2 consist almost exclusively of a nuclear transport factor 2-like domain (NTF2LD). NXF1 exhibits a nuclear localization signal (NLS), an RNA recognition motif domain (RRMD), four leucine-rich repeats (LRR), an NTF2-like domain and a C-terminal nuclear pore binding domain (C-term. NPC-binding domain). NXF2 shows a similar protein structure. NXF3 is lacking the C-terminal NPC-binding domain but gained an exportin (XPO1) binding site.




Supplementary Figure 3. Western blot analysis of NXF2 and NXF3 proteins expressed from deletion constructs lacking the NTF2-like domain or RRM domain.

a. The deletion of the NTF2-like domain and the RRM domain from the NXF2-FLAG expression construct results in the expression of truncated NXF2 proteins, when overexpressed in HEK cells, as visualized using a FLAG antibody in a Western blot. Calculated molecular weights are ~72 kDa for full-length NXF2-FLAG, ~55 kDa for NXF2^{NTF2LDdel}-FLAG, and ~63 kDa for NXF2^{RRMDdel}-FLAG. b. Western blot analysis of lysates derived from overexpression of NXF3 deletion constructs in HEK cells demonstrating expression of truncated FLAG-tagged NXF3 proteins compared to the wildtype. Calculated molecular weights are ~60 kDa for full-length NXF3-FLAG, ~43 kDa for NXF3^{NTF2LDdel}-FLAG, and ~51 kDa for NXF3^{RRMDdel}-FLAG. Uncropped images of all Western blots depicted are provided in the Source data file.




Supplementary Figure 4. The NXT2 protein region downstream of the NTF2-like domain is not essential for binding to NXF2 and NXF3.

a. Deletion of six C-terminal amino acids of NXT2-HA, located downstream of the predicted NTF2-like domain (amino acids 192-197 in NM_018698.5) truncates the protein. b. The C-terminal truncated NXT2-HA protein is still able to bind to NXF2-FLAG as demonstrated by Co-IP of protein lysates obtained from NXT2 and NXF2 constructs overexpressed in HEK293T cells and visualized in a Western blot. The top Western blot refers to protein lysates, while the bottom blot is derived from Co-IP. c. The interaction between NXT2^{AA192-197del}-HA and NXF3-FLAG persists even without the C-terminus of NXT2. Lysates are visualized at the top, Co-IP-samples at the bottom. Western blots demonstrate representative results of at least three replicates. Uncropped images of all Western blots depicted are provided in the Source data file.



Supplementary Figure 5. The *NXT2* missense variant c.268G>T p.(Ala90Ser) in M2004 has an impact on splicing but no identified effect on the protein level.

a. M2004 is positive for the hemizygous single nucleotide substitution c.268G>T in *NXT2* affecting the most 5' nucleotide of exon four. DNA samples of other family members were not available for co-segregation analysis. b. In a minigene assay, the variant c.268G>T in *NXT2* leads to a skipping of exon 4 in a minor proportion of transcripts *in vitro*, resulting in a frameshift [r.268_412del p.(Ala90Serfs*13)]. c. The affected alanine residue is conserved in orthologs of *NXT2* across bovine, mouse and chicken. In the paralog human protein *NXT1*, the amino acid is not preserved. d. AlphaFold2 predictions show wildtype, mutant (substituted residue = red) and truncated (loss of 107 amino acids caused by exon skipping) *NXT2* 3D structures. e, Western blot of overexpressed wildtype and mutant *NXT2* p.(Ala90Ser) demonstrated no effect of the amino acid substitution on protein stability. f, When overexpressed in HEK cells, *NXT2* p.(Ala90Ser) and *NXF2* are detectable (~26 kDa for *NXT2* and ~72 kDa for *NXF2*) in a Western blot of cell lysates (left). The *NXT2* p.(Ala90Ser) variant does not impair binding to *NXF2* as shown by Co-IP experiments (right). g. Binding of *NXT2* p.(Ala90Ser) to *NXF3* is also not affected as shown by Co-IP. Western blots demonstrate representative results of at least three replicates. Uncropped images of all Western blots depicted are provided in the Source data file. h. Immunohistochemical staining of *NXT2* in M2004 compared to control tissue demonstrated that *NXT2* is still expressed in SOX9-positive Sertoli cells.



Supplementary Figure. 6. scRNA-seq shows expression of nuclear export factor proteins in fetal male germ cells and adult testis.

a. scRNA-seq dataset of fetal male germ cells² was analyzed via smart-DB³. *NXT2* reveals a strong expression in germ cells. *NXF1* is mainly expressed in fetal Leydig and in Sertoli cells. *NXF2* is generally weakly expressed and *NXF3* is expressed in fetal Sertoli but not in germ cells. b. In the adult testis, different scRNA-seq datasets^{4,5} showed different expression patterns: Sohn et al. show *NXT2* expression mainly in spermatogonia, but also in spermatocytes and spermatids⁴. *NXF1* is ubiquitously expressed, *NXF2* is expressed in spermatogonia and spermatocytes and *NXF3* is mainly expressed in spermatids (left)⁴. In the dataset of Zhao et al. (right)⁵ *NXT2*, *NXF1* and *NXF3* are also expressed in Sertoli cells (EC:

endothelial cells; FLC: fetal Leydig cells; LC: Leydig cells; SC: Sertoli cells; GC: germ cells; SPG: spermatogonia; SPC: spermatocytes; SD: spermatids).

Supplementary References

1. Oud, M. S. *et al.* A de novo paradigm for male infertility. *Nat. Commun.* **13**, 154 (2022).
2. Garcia-Alonso, L. *et al.* Single-cell roadmap of human gonadal development. *Nature* **607**, 540–547 (2022).
3. Liu, Z. *et al.* SMARTdb: An Integrated Database for Exploring Single-cell Multi-omics Data of Reproductive Medicine. *Genomics. Proteomics Bioinformatics* **38**, e102870 (2024).
4. Sohni, A. *et al.* The Neonatal and Adult Human Testis Defined at the Single-Cell Level. *Cell Rep.* **26**, 1501-1517.e4 (2019).
5. Zhao, L. Y. *et al.* Single-cell analysis of developing and azoospermia human testicles reveals central role of Sertoli cells. *Nat. Commun.* **11**, 5683 (2020).